Skip to content

Research / Diseases

Parkinson’s Disease

Parkinson's disease (PD) is characterized by the progressive loss of dopamine-producing neurons in the brain due to misfolding of a neuroprotein called alpha-synuclein.

Two scientists at the Opentrons liquid-handling robot in the Brain Chemistry Labs laboratory
Section 01The disease

The lack of dopamine disrupts communication between neurons that control movement. By the time motor symptoms appear and PD is diagnosed, a substantial proportion of dopaminergic neurons have already been lost.

PD is known as a “synucleinopathy,” which means that the disease is characterized by the accumulation of pathological alpha-synuclein. It misfolds and clumps into aggregates that accumulate in the brain and are thought to contribute to cell death and disease onset.

Section 02Current treatment

Levodopa, introduced more than 60 years ago, was a miracle drug in helping to control Parkinson’s symptoms. It is highly effective early on, but its benefit declines as the disease progresses, and long-term use can induce dyskinesias in many patients. Levodopa treats symptoms only, does not stop protein misfolding, and no approved therapy slows or halts the underlying neurodegeneration.

Section 03Our work

At Brain Chemistry Labs, we have identified a naturally occurring molecule that, in preclinical studies, significantly reduces misfolding and aggregation of alpha-synuclein.

Brain Chemistry Labs is planning a Phase II clinical trial in patients with PD to test the efficacy of this naturally occurring molecule. Subject to FDA clearance, the trial is expected to begin in 2027.

Section 04A blood test

Simultaneously, Brain Chemistry Labs is also developing a miRNA blood test to identify PD in patients and assist clinicians in making an earlier diagnosis. This test will follow the same CLIA/CAP validation as the ALS Test.

Section 05References
Clinical trial

Phase II

Planned, to test a naturally occurring molecule against alpha-synuclein misfolding. Subject to FDA clearance, expected to begin in 2027.

  • TargetAlpha-synuclein
  • PreclinicalReduced misfolding
  • Trial start2027, subject to FDA
  • Blood testmiRNA, in development
Fund this work
Section 05From misfolding to a trial

A natural molecule against misfolding.

Levodopa treats symptoms only, does not stop protein misfolding, and no approved therapy slows or halts the underlying neurodegeneration.

01ALPHA-SYNUCLEIN MISFOLDSClumps into aggregates thataccumulate in the brain02DOPAMINE NEURONS LOSTMuch of the loss happensbefore motor symptoms appear03A NATURAL MOLECULEReduced misfolding and aggregationin preclinical studies04PHASE II TRIALExpected to begin in 2027,subject to FDA clearance